The human visual system’s capacity to perceive the chromatic spectrum depends upon a remarkably delicate cascade of neurobiological, photochemical, and cortical mechanisms. While hereditary color vision deficiencies are widely recognized genetic conditions, acquired color blindness—clinically termed acquired dyschromatopsia—manifests as an unexpected, often progressive impairment in color perception resulting from disease, toxic exposure, trauma, or cortical damage. Understanding this sensory loss provides profound insights into the functional architecture of human vision, spanning from photoreceptor transduction in the retina to higher-order processing in extrastriate visual pathways.
Acquired Color Blindness
1. Concise Definition
Acquired color blindness is an acquired impairment or total loss of chromatic discrimination resulting from pathological alterations to the ocular media, photoreceptor matrix, optic nerve, or the central visual pathways, rather than an inherited genetic mutation. Unlike congenital color vision defects, which are virtually always bilateral, symmetric, stationary, and predominantly X-linked red-green deficiencies, acquired dyschromatopsia can be unilateral, asymmetric, progressive, fluctuating, or reversible depending upon the underlying etiology.
Clinically, the condition ranges from mild desaturation and subtle tint alterations to complete achromatopsia, wherein the visual world is rendered entirely in monochromatic shades of gray. Because the pathology disrupts an already mature, calibrated visual apparatus, patients with acquired color blindness are typically acutely conscious of their sensory alteration, frequently reporting that colors appear washed out, dirty, brownish, or fundamentally distorted compared to their prior perceptual baseline.
2. Etymology & Linguistic Origin
The term acquired derives from the Latin acquirere (compounded from ad-, meaning “to” or “in addition to,” and quaerere, meaning “to seek” or “obtain”), indicating a condition obtained during one’s lifetime rather than inherited at conception. The word color originates from Old French colour, stemming directly from the Classical Latin color (originally colos), denoting hue, complexion, or outward appearance. Blindness descends from the Proto-Germanic *blindaz, meaning “cloudy,” “murky,” or “sightless,” affixed with the Old English abstract noun suffix -ness.
In specialized neuro-ophthalmic discourse, practitioners commonly employ the Greek-derived term acquired dyschromatopsia. This clinical designation combines the prefix dys- (bad, abnormal, or disordered), chroma (color), and opsis (sight or vision). When the deficit results from localized focal lesions in the occipitotemporal cortex, the diagnostic terminology transitions to cerebral achromatopsia (from the Greek privative a-, meaning “without”), denoting an absolute loss of central color processing despite intact retinal function.
3. Pronunciation & Grammatical Form
Pronunciation: /əˈkwaɪ.əd ˈkʌl.ər ˈblaɪnd.nəs/ (British English) or /əˈkwaɪ.ɚd ˈkʌl.ɚ ˈblaɪnd.nəs/ (American English). The formal clinical counterpart, acquired dyschromatopsia, is pronounced /əˈkwaɪərd ˌdɪs.kroʊ.məˈtɒp.si.ə/.
Grammatical Form: Compound noun phrase. The term functions syntactically as an uncountable noun (e.g., “The patient presented with progressive acquired color blindness”). The adjectival modification can be rendered as dyschromatopsic or applied directly through phrasal descriptors (e.g., “acquired color-deficient vision”).
4. Detailed Conceptual Explanation
Color perception begins when incident photons strike three functionally distinct classes of retinal cone photoreceptors: short-wavelength-sensitive (S-cones, peak ~420 nm), medium-wavelength-sensitive (M-cones, peak ~530 nm), and long-wavelength-sensitive (L-cones, peak ~560 nm). The phototransduction cascade initiates neural signals that are processed and separated into chromatic opponent channels within the retinal ganglion cells: the parvocellular pathway (mediating red-green opponency) and the koniocellular pathway (mediating blue-yellow opponency). These specialized channels project via the optic nerve and chiasm to distinct laminae within the lateral geniculate nucleus (LGN) of the thalamus, which subsequently relay signals to the primary visual cortex (striate cortex, Area V1 / Brodmann Area 17).
From Area V1, chromatic information traverses the cytochrome oxidase-rich “blobs” and passes to the “thin stripes” of Area V2. It is then routed along the ventral visual stream—the specialized neural “what” pathway—into extrastriate areas designated as the V4 complex and the ventral occipital (VO) cortex, encompassing portions of the lingual and fusiform gyri. Acquired color blindness emerges when structural, metabolic, toxic, or ischemic insults interrupt this pathway at any anatomical locus from the pre-receptoral media to the ventral occipitotemporal cortex.
The scope of acquired color deficiency differs fundamentally from congenital defects. While congenital forms are almost exclusively stable red-green (protan or deutan) deficits caused by mutations in the OPN1LW or OPN1MW opsin genes on the X chromosome, acquired defects encompass a significant proportion of tritan (blue-yellow) anomalies. Furthermore, acquired forms rarely present in isolation; they are frequently accompanied by associated visual dysfunctions, such as reduced visual acuity, visual field defects, contrast sensitivity loss, metamorphopsia, or visual object agnosia.
The biological boundaries of acquired color vision impairment are delineated by the anatomical site of pathology. Pre-receptoral etiologies, such as nuclear sclerotic cataracts, alter chromatic perception through mechanical light absorption, selectively filtering shorter blue wavelengths without damaging neural pathways. Retinal and macular etiologies disrupt cone density, outer segment alignment, or retinal pigment epithelium (RPE) metabolism. Optic nerve pathologies impede axonal conduction via demyelination or ischemia, while cortical etiologies leave the peripheral sensory organ entirely functional but destroy the neural computational networks responsible for synthesizing color from wavelength ratios.
5. Historical Development
The systemic study of color blindness began in earnest with John Dalton’s 1798 personal account of his own hereditary condition. However, clear differentiation between congenital and acquired color deficits did not crystallize until the late nineteenth century. Early ophthalmologists noted that patients presenting with systemic neurosyphilis, toxic amblyopia from tobacco and alcohol, or traumatic brain injury exhibited erratic, deteriorating color sensitivity that deviated markedly from classical congenital Daltonism.
In 1888, the Swiss ophthalmologist Louis Verrey documented the seminal clinical case of acquired cerebral achromatopsia. Verrey described a 60-year-old woman who, following a localized stroke affecting the left occipital lobe, suffered an isolated loss of color vision in her right visual hemifield (hemiachromatopsia) while preserving normal visual acuity and form perception. Verrey deduced that a discrete “center for chromatic sense” existed in the lingual and fusiform gyri of the inferior human visual cortex. His radical assertion was met with skepticism by contemporary neurologists who subscribed to non-localized sensorimotor models.
In 1912, German ophthalmologist Köllner’s rule was established. Paul Köllner formulated an empirical clinical maxim: acquired blue-yellow (tritan) defects typically originate from outer retinal, choroidal, and macular lesions, whereas acquired red-green (protan-deutan) defects point directly to pathology of the inner retina, optic nerve, and retrobulbar pathways. Although subsequent modern research demonstrated critical exceptions to this rule, it provided the first structured diagnostic framework for clinical localization using color vision testing.
The latter half of the twentieth century witnessed a technological revolution in the neuroscience of color processing. Semir Zeki’s electrophysiological discoveries in primates during the 1970s confirmed the presence of color-selective neurons in cortical area V4, corroborating Verrey’s historic hypotheses. This era was immortalized in popular neuro-anthropology by Oliver Sacks and Robert Wasserman in their 1987 study (and subsequent 1995 book chapter), The Case of the Colorblind Painter, which chronicled the life of “Jonathan I.,” an artist who lost all chromatic perception following a traumatic cerebral stroke, highlighting the profound cognitive, emotional, and sensory disruptions of acquired cortical achromatopsia.
6. Theoretical Foundations
Acquired color blindness intersects directly with three major theoretical paradigms of visual science: Trichromatic Theory, Opponent-Process Theory, and Edwin Land’s Retinex Theory.
The Trichromatic Theory (formulated by Thomas Young and refined by Hermann von Helmholtz) explains how three distinct receptor types in the retina sample the electromagnetic spectrum. In acquired color blindness, localized pathology—such as macular telangiectasia, age-related macular degeneration (AMD), or central serous chorioretinopathy—physically impairs the structural integrity, spatial arrangement, or photopigment density of these cone outer segments. Selective biological vulnerability often targets S-cones, which constitute only 5% to 10% of the retinal cone mosaic and are uniquely susceptible to oxidative stress, mechanical stretching, and metabolic ischemia.
The Opponent-Process Theory, advanced by Ewald Hering, posits that post-receptoral neural circuitry encodes color along three antagonistic axes: red versus green, blue versus yellow, and black versus white (luminance). Acquired color blindness illustrates how retro-receptoral diseases dissect these distinct channels. For instance, demyelinating conditions such as optic neuritis severely disrupt the parvocellular pathways responsible for red-green signaling, resulting in dramatic “red desaturation” even before broad visual acuity declines.
At the highest perceptual level, Edwin Land’s Retinex Theory demonstrates that color is not merely a passive reading of reflected wavelengths, but an active cortical computation that calculates the reflectance of surfaces relative to their visual surroundings, producing color constancy under varying illumination. Cerebral achromatopsia dismantles this computational architecture. Patients with acquired cortical damage cannot synthesize these relational spectral equations; though their retinas transmit raw wavelength variations to the thalamus and primary visual cortex, the damaged ventral occipital extrastriate cortex fails to transform wavelength information into unified conscious color experiences.
7. Key Components, Types & Dimensions
Acquired color vision deficiencies are categorized along anatomical, chromatic, and clinical axes:
- Verriest’s Clinical-Pathological Classification (Modern Adaptation of Köllner’s Rule):
- Type I Red-Green Defect: Marked by a progressive loss of red-green discrimination with an accompanying shift in the luminous efficiency curve toward shorter wavelengths. Typically associated with juvenile macular dystrophies, cone-rod degenerations, and progressive Stargardt disease.
- Type II Red-Green Defect: Characterized by severe loss of red-green discrimination without significant changes to luminosity, accompanied by substantial reduction in visual acuity. Frequently seen in retrobulbar optic neuritis, optic nerve compression, and toxic/nutritional optic neuropathies.
- Type III Blue-Yellow Defect: Characterized by loss of tritan discrimination. Frequently observed in diabetic retinopathy, retinal vascular occlusions, early-stage glaucoma, age-related macular degeneration, central serous chorioretinopathy, and chorioretinitis.
- Cerebral Achromatopsia vs. Hemiachromatopsia:
- Full Cerebral Achromatopsia: Bilateral loss of color perception across the entire visual field following bilateral lesions (often ischemic strokes involving the posterior cerebral arteries) of the lingual and fusiform gyri. Visual acuity, depth perception, and motion detection often remain intact.
- Hemiachromatopsia: Unilateral loss of chromatic perception confined strictly to the contralateral visual hemifield following a unilateral cortical lesion, demonstrating the retinotopic organization of higher-order color centers.
- Chromatopsia (Color Tints):
- Abnormal subjective experiences where the visual field is washed in a uniform chromatic cast. Examples include xanthopsia (yellow vision, classically associated with digitalis/digoxin toxicity), cyanopsia (blue vision, associated with sildenafil citrate or cataract removal), and erythropsia (red vision, frequently reported following intense ultraviolet exposure or vitreous hemorrhage).
- Toxic and Drug-Induced Dyschromatopsia:
- Color vision loss secondary to systemic medications or environmental toxins, including ethambutol (tuberculosis therapy, inducing optic neuropathy), hydroxychloroquine (bull’s-eye maculopathy), heavy metals (lead, mercury), and industrial organic solvents (toluene, styrene).
8. Examples & Illustrative Cases
Case Illustration 1: Acute Demyelinating Optic Neuritis. A 28-year-old woman presents to an emergency ophthalmic clinic complaining of dull retrobulbar pain exacerbated by eye movement, accompanied by a rapid loss of visual clarity in her left eye over three days. While her Snellen visual acuity is moderately reduced to 20/40, her subjective chief complaint is that the brake lights of vehicles appear “drab, dirty brown, and drained of vitality.” Clinical confrontation testing reveals severe red desaturation: a bright scarlet target appears vivid red in the right eye but faded orange-gray in the left. Automated testing confirms a profound acquired Type II red-green defect alongside an afferent pupillary defect (Marcus Gunn pupil), confirming demyelinating optic neuritis suggestive of multiple sclerosis.
Case Illustration 2: Cerebral Achromatopsia Following Posterior Cerebral Artery Stroke. A 62-year-old commercial photographer suffers bilateral ischemic strokes in the territories of the posterior cerebral arteries, injuring the ventral occipital cortices. Upon stabilization, neurological assessment confirms normal visual fields, preserved pupillary reflexes, and 20/25 visual acuity. However, the patient is completely incapable of perceiving color. He describes the world as an old black-and-white television broadcast, describing food as unappetizing due to its uniform grayscale appearance. While he can easily name objects, read text, and detect fine motion, he fails every plate of the Ishihara and Farnsworth-Munsell tests, demonstrating acquired cortical achromatopsia.
Case Illustration 3: Toxic Optic Neuropathy from Ethambutol Therapy. A 54-year-old male undergoing therapy for multi-drug-resistant pulmonary tuberculosis notices progressive difficulty differentiating traffic signals over four weeks. Snellen acuity is 20/30 bilaterally, but color testing via the Farnsworth-Munsell D-15 reveals combined red-green and blue-yellow errors. Immediate cessation of ethambutol halts toxic mitochondrial disruption within the papillomacular bundle of the optic nerve, resulting in full chromatic recovery over nine months.
9. Measurement & Assessment
Diagnosing acquired color vision deficiencies requires specialized tools, because clinical tests designed for congenital defects frequently fail to detect or properly characterize acquired dyschromatopsia.
Pseudoisochromatic Plates: Traditional screening plates like the standard Ishihara test are exclusively engineered to detect congenital red-green deficiencies; they contain no blue-yellow (tritan) plates and are therefore insufficient for diagnosing the majority of retinal and early glaucomatous acquired conditions. In contrast, the Hardy-Rand-Rittler (HRR) pseudoisochromatic plates include dedicated tritan plates and graded saturation steps, making them far more effective for detecting acquired ocular pathologies.
Arrangement Tests: The gold standard for categorizing and quantifying acquired color vision loss is hue arrangement:
- Farnsworth-Munsell 100 Hue Test (FM-100): Consists of 85 color caps spanning the entire spectrum at constant lightness and saturation. The patient arranges them in chromatic order. Error patterns plotted on polar coordinate charts permit precise identification of tritan, protan, and deutan axes, as well as general non-specific dyschromatopsias associated with diffuse neural injury.
- Farnsworth Panel D-15: A rapid, 15-cap screening version of the FM-100 designed to identify moderate-to-severe color vision defects, isolating specific axes of confusion within two minutes per eye.
Anomaloscopy: The Nagel Anomaloscope represents the definitive instrument for measuring the Rayleigh match (a mixture of red and green spectral lights matched to a spectral yellow). While indispensable for classifying congenital protan and deutan anomalies, its utility in acquired color blindness is often constrained by its demand for high visual acuity and its restriction to the red-green axis. The Pickford-Nicolson and Moreland anomaloscopes expand this methodology by integrating the Moreland match (blue and green matched to a cyan-blue mixture), directly assessing tritan defects.
Electrophysiological and Structural Imaging Diagnostics: In clinical neurology and ophthalmology, functional color deficits are correlated with objective physical measurements:
- Optical Coherence Tomography (OCT): High-resolution cross-sectional retinal imaging assesses the integrity of the photoreceptor ellipsoid zone and ganglion cell complex, locating retinal sources of dyschromatopsia.
- Visual Evoked Potentials (VEP): Chromatic pattern-reversal VEPs measure conduction velocities through the optic nerve, highlighting demyelinating delays even when baseline visual acuity remains intact.
- Functional Magnetic Resonance Imaging (fMRI): Neuroimaging isolates ischemic, neoplastic, or hemorrhagic lesions within the ventral occipitotemporal cortex (fusiform and lingual gyri), confirming suspected cerebral achromatopsia.
10. Applications & Practical Significance
The clinical assessment of acquired color vision serves as a sensitive diagnostic, monitoring, and occupational biomarker across multiple disciplines:
Early Neuro-Ophthalmic Diagnosis: Color vision deficits frequently precede reductions in visual acuity and standard automated perimetry visual field loss. In optic neuropathies—such as compressive tumors, Leber’s hereditary optic neuropathy, or optic neuritis—chromatic desaturation is often the earliest identifiable clinical sign. Routine color assessment serves as a frontline defense against permanent neurological morbidity.
Pharmacovigilance and Toxicological Screening: Routine chromatic screening is essential for patients undergoing long-term treatment with potentially retinotoxic or neurotoxic pharmacotherapies. Routine testing protects patients using medications such as hydroxychloroquine (for rheumatoid arthritis and lupus), ethambutol (for tuberculosis), vigabatrin (for epilepsy), and sildenafil (for pulmonary arterial hypertension or erectile dysfunction), pinpointing toxicities while they remain clinically reversible.
Occupational and Environmental Health: Workers exposed to neurotoxic volatile organic solvents (such as styrene, toluene, xylene, and perchloroethylene) in industrial printing, chemical manufacturing, and dry cleaning exhibit subclinical tritan dyschromatopsias. Implementing routine color arrangement evaluations enables occupational health physicians to detect neurotoxicity early, prompting engineering improvements before irreversible central nervous system injury occurs.
Aviation and Maritime Safety: Because acquired color vision deficits can develop insidiously in previously normal individuals due to underlying systemic health issues (such as uncontrolled diabetes or open-angle glaucoma), commercial pilots, maritime captains, and rail operators undergo periodic chromatic re-evaluations to ensure public transportation safety.
11. Research & Empirical Evidence
Modern empirical research has transformed our understanding of how neurodegenerative conditions systematically affect the visual pathways. In Alzheimer’s Disease and Parkinson’s Disease, pathological processes extend far beyond motor and memory circuits. Landmark studies by researchers such as Armstrong (2009) and Archibald et al. (2011) demonstrate that patients with Parkinson’s disease exhibit early tritan and blue-yellow chromatic discrimination defects. This impairment correlates with the progressive depletion of dopaminergic amacrine cells within the inner plexiform layer of the retina, establishing chromatic testing as a non-invasive behavioral biomarker for neurodegenerative progression.
In systemic metabolic research, extensive clinical studies demonstrate that diabetic retinopathy causes subtle tritan color discrimination deficits years before microvascular abnormalities, hemorrhages, or exudates become visible on standard funduscopic examination. Research by Roy et al. indicates that metabolic changes within the neural retina (neuroretinopathy) precede microvascular damage, highlighting the utility of color thresholds in tracking subclinical diabetic complications.
Cognitive neuroscience continues to explore the exact architecture of cortical color representation. Human neuroimaging studies spearheaded by Semir Zeki, followed by detailed lesion-mapping investigations by Bartels and Zeki (2000) and Wandell et al. (2007), have clearly delineated the human VO (Ventral Occipital) complex. Their findings confirm that while Area V1 separates chromatic signals, conscious chromatic perception, color constancy, and categorical color cognition rely on specialized computational networks within the collateral sulcus, lingual gyrus, and fusiform gyrus.
12. Cultural & Cross-Cultural Considerations
The subjective experience and diagnostic reporting of acquired color blindness vary significantly across linguistic and cultural boundaries. Cross-cultural vision science, drawing upon the Sapir-Whorf linguistic relativity framework and the seminal work of Berlin and Kay (1969), demonstrates that societies categorize and label the visible spectrum differently. In languages that lack separate lexical distinctions for blue and green (often grouped linguistically as “grue,” as observed in diverse indigenous languages across Oceania, Africa, and the Americas), subjective patient reports of acquired tritan dyschromatopsia may differ noticeably from descriptions provided by speakers of languages with fine-grained color terminologies.
Furthermore, disparities in access to medical infrastructure create cross-cultural variations in the clinical presentation of acquired color blindness. In lower- and middle-income regions, where environmental and occupational regulations may be less rigorously enforced, the incidence of severe toxic dyschromatopsias caused by industrial solvents, heavy metals, and uncontrolled use of medications like ethambutol is substantially higher. Moreover, screening batteries like the Ishihara test—which relies on Arabic numerals—pose diagnostic barriers for non-numerate or illiterate populations, necessitating the validation and deployment of universal, non-verbal chromatic tests (such as symbol-based HRR plates or automated computerized matching algorithms) to prevent global misdiagnosis.
13. Criticisms, Debates & Limitations
Despite centuries of scientific inquiry, clinical controversies and theoretical debates persist regarding acquired color vision deficits:
Limitations of Köllner’s Rule: While Köllner’s rule remains a staple of ophthalmic education, modern clinical investigations consistently identify major exceptions. For example, glaucoma is an optic nerve disease that primarily causes tritan (blue-yellow) defects rather than red-green defects, contradicting Köllner’s classic dictum. Similarly, dominant optic atrophy manifests primarily as a blue-yellow deficiency, whereas cone dystrophies (retinal disorders) cause severe red-green deficits. Consequently, clinicians are cautioned against using Köllner’s rule as an absolute localizing tool in the absence of comprehensive structural and electrophysiological evaluations.
The Modularity of Area V4: Neuroscientists continue to debate the functional modularity of the ventral visual stream. While early researchers argued for a dedicated, modular “color center” in human Area V4, contemporary systems neuroscientists suggest that color, form, and texture processing are heavily integrated within a distributed network of multipotential cortical nodes. Critics argue that “pure” cerebral achromatopsia is exceptionally rare precisely because brain lesions seldom spare the adjacent cortical machinery responsible for reading (alexia) and face recognition (prosopagnosia).
Nomenclature Ambiguity: Medical literature frequently uses the terms “color blindness,” “color deficiency,” and “dyschromatopsia” interchangeably. Purists argue that the phrase “acquired color blindness” is clinically misleading, as total chromatic blindness (achromatopsia) is exceptionally rare compared to partial, selective chromatic desaturation. This linguistic ambiguity can trigger unnecessary distress in patients who receive a diagnosis of color deficiency but mistakenly believe they face total black-and-white vision.
14. Related Terms & Distinctions
- Congenital Color Vision Deficiency: A stationary, genetically determined defect present from birth, primarily inherited in an X-linked recessive pattern (affecting approximately 8% of males and 0.5% of females of Northern European ancestry). Unlike acquired forms, it is invariably symmetric, bilateral, stable, and unaccompanied by loss of visual acuity or visual field defects.
- Cerebral Achromatopsia: A subtype of acquired color blindness caused by direct cortical injury to the ventral occipitotemporal cortex. Peripheral retinal receptors and the anterior visual pathways remain functional, but the brain cannot generate chromatic percepts from incoming signals.
- Visual Agnosia: A higher-order cognitive deficit where an individual cannot recognize visual objects despite intact basic visual faculties. In color agnosia, patients can discriminate colors accurately on arrangement tests but cannot identify, name, or associate colors with common objects (e.g., failing to remember that a banana is yellow).
- Color Anomia: A language-specific deficit where the patient perceives and discriminates colors normally and understands chromatic concepts, but cannot verbally state the names of colors due to an interruption of pathways connecting the visual cortex to language centers in the left hemisphere.
- Chromatopsia: An acquired distortion of visual perception characterized by an abnormal overall color tint across the entire visual field (e.g., xanthopsia, cyanopsia, erythropsia), rather than an inability to discriminate between specific hues.
15. Summary / Key Takeaways
Acquired color blindness is a multifaceted sensory deficit resulting from damage sustained by previously healthy visual pathways. Whether triggered by retinal degeneration, metabolic disease, neurotoxins, demyelination, or cortical stroke, it differs sharply from congenital color blindness in its capacity to fluctuate, its frequent presentation with blue-yellow (tritan) defects, its potential asymmetry between eyes, and its co-occurrence with other visual impairments. Applying comprehensive clinical evaluations—including pseudoisochromatic plates with tritan testing, cap arrangement assays, optical coherence tomography, and functional neuroimaging—enables clinicians and researchers to identify underlying systemic, neurologic, and environmental conditions early, protecting both visual function and systemic health.
References
- Archibald, N. K., Clarke, M. P., Mosimann, U. P., & Burn, D. J. (2011). Visual symptoms in Parkinson’s disease devices and therapies. Movement Disorders, 26(13), 2387–2395. https://doi.org/10.1002/mds.23893
- Bartels, A., & Zeki, S. (2000). The architecture of the colour centre in the human visual brain: New results and a review. European Journal of Neuroscience, 12(1), 172–193. https://doi.org/10.1046/j.1460-9568.2000.00905.x
- Köllner, P. (1912). Die Störungen des Farbensinnes: Ihre klinische Bedeutung und ihre Diagnose. Karger Publishers.
- Meadows, J. C. (1974). Disturbed perception of colours associated with localized cerebral lesions. Brain, 97(4), 615–632. https://doi.org/10.1093/brain/97.4.615
- Pokorny, J., Smith, V. C., Verriest, G., & Pinckers, A. J. L. G. (1979). Congenital and Acquired Color Vision Defects. Grune & Stratton.
- Sacks, O., & Wasserman, R. (1987). The case of the colorblind painter. The New York Review of Books, 34(18), 25–33.
- Verrey, L. (1888). Hémiachromatopsie droite absolue. Archives d’Ophtalmologie (Paris), 8, 289–300.
- Wandell, B. A., Dumoulin, S. O., & Brewer, A. A. (2007). Visual field maps in human cortex. Neuron, 56(2), 366–383. https://doi.org/10.1016/j.neuron.2007.10.012
- Zeki, S. (1990). A century of cerebral achromatopsia. Brain, 113(6), 1721–1777. https://doi.org/10.1093/brain/113.6.1721